Combining Rosuvastatin with Sartans of Different Peroxisome Proliferator-Activated Receptor-gamma Activating Capacity Is Not Associated with Different Changes in Low-Density Lipoprotein Subfractions and Plasma Lipoprotein-Associated Phospholipase A(2)
Φόρτωση...
Ημερομηνία
Συγγραφείς
Rizos, C. V.
Liberopoulos, E. N.
Tellis, C. C.
Florentin, M.
Elisaf, M. S.
Tselepis, A. D.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Metabolic Syndrome and Related Disorders
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
Background: Rosuvastatin reduces low-density lipoprotein cholesterol (LDL-C) and plasma lipoprotein-associated phospholipase A(2) (Lp-PLA(2)). Some sartans partially activate peroxisome proliferator-activated receptor-g (PPAR gamma), possibly having a favorable effect on metabolic parameters. Telmisartan is the most potent partial PPAR gamma activator, followed by irbesartan, whereas olmesartan does not hold such capacity. In an open-label randomized study, we assessed the effects of combining sartans of different PPAR gamma-activating capacity with rosuvastatin on LDL subfractions and plasma Lp-PLA(2) in patients with mixed dyslipidemia, hypertension, and prediabetes. Methods: Following dietary intervention, patients were allocated randomly to rosuvastatin (10 mg/day) plus telmisartan 80 mg/day (RT group, n - 52) or irbesartan 300 mg/day (RI group, n - 48) or olmesartan 20 mg/day (RO group, n - 51). After 6 months of treatment, changes in LDL subfraction cholesterol and plasma Lp-PLA(2) activity and mass were evaluated blindly. Results: A total of 151 patients (73 male; mean age 60 years) were included. Large LDL-C decreased in the RT (-36%), RI (-39%), and RO (-41%) groups (P<0.001 for all vs. baseline). Small dense LDL-C decreased in the RT (-67%), RI (-58%), and RO (-61%) groups (P<0.001 for all vs. baseline). All regimens increased LDL particle size versus baseline (RT+1.4%, P = 0.002; RI+1.0%, P = 0.04; and RO+1.4%, P = 0.001). No difference for the change of LDL subfractions and LDL size was noticed among groups. Plasma Lp-PLA(2) activity decreased equally in all groups (RT -38%, RI -38%, RO -43%) (P<0.001 for all vs. baseline). Plasma Lp-PLA(2) mass decreased similarly in all groups versus baseline (RT -28%, P = 0.001; RI -32%, P = 0.01; and RO -27%, P = 0.001). No difference for the change of Lp-PLA(2) mass or activity was noticed among groups. Conclusions: The combination of rosuvastatin with sartans of different PPAR gamma-activating capacity did not differentiate alterations of LDL subfraction cholesterol and plasma Lp-PLA(2) activity and mass.
Περιγραφή
Λέξεις-κλειδιά
coronary-heart-disease, ldl particle-size, acetylhydrolase activity, insulin sensitivity, hypolipidemic drugs, hypertension, telmisartan, risk, atherosclerosis, identification
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
<Go to ISI>://000291001200009
http://online.liebertpub.com/doi/pdfplus/10.1089/met.2010.0120
http://online.liebertpub.com/doi/pdfplus/10.1089/met.2010.0120
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας